LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

NCT00550277 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: LBH589

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]